ReviewCNS & neurological disorders drug targets2009
Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Review in CNS & neurological disorders drug targets, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Let's make microglia great again in neurodegenerative disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Bacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloid.Aging · 2016Article
- Amyloid-β immunization enhances neurogenesis and cognitive ability in neonatal mice.International journal of clinical and experimental medicine · 2015Article
- Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Pharmacology & therapeutics · 2013Review
- Brain injury, neuroinflammation and Alzheimer's disease.Frontiers in aging neuroscience · 2013Article
- TGFβ signalling plays an important role in IL4-induced alternative activation of microglia.Journal of neuroinflammation · 2012Article
- New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.British journal of clinical pharmacology · 2012Review
- Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity.Neural plasticity · 2012Review
- Article
- How to get from here to there: macrophage recruitment in Alzheimer's disease.Current Alzheimer research · 2011Review
- Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology.Journal of cellular and molecular medicine · 2011Article
- Natural products as a source of Alzheimer's drug leads.Natural product reports · 2011Review
- Macrophages in Alzheimer's disease: the blood-borne identity.Journal of neural transmission (Vienna, Austria : 1996) · 2010Review
- Current therapies and new strategies for the management of Alzheimer's disease.American journal of Alzheimer's disease and other dementias · 2010Review
- Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.Expert review of neurotherapeutics · 2010Review
- Article
- Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease.Cardiovascular psychiatry and neurology · 2010Article
- CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2009Review
- Can peripheral leukocytes be used as Alzheimer's disease biomarkers?Expert review of neurotherapeutics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In a seminal report in 1999, Schenk and colleagues demonstrated that vaccination of a mouse model of Alzheimer's disease (AD) with amyloid-beta(1-42) peptide (Abeta(1-42)) and adjuvant resulted in striking mitigation of AD-like pathology - giving rise to the field of AD immunotherapy. Later studies confirmed this result in other mouse models of AD and additionally showed cognitive improvement after Abeta vaccination. Based on these results, early developmental clinical trials ensued to immunize AD patients with Abeta(1-42) plus adjuvant (so-called "active" Abeta immunotherapy; trade name AN-1792; Elan Pharmaceuticals, Dublin, Ireland). However, the phase IIa trial was halted after 6 % of patients developed aseptic meningoencephalitis. Despite occurrence of this adverse event, many individuals demonstrated high serum antibody titres to Abeta and histological evidence of clearance of the hallmark AD pathology, beta-amyloid plaques. While raising justifiable safety concerns, these important results nonetheless demonstrated the feasibility of the active Abeta immunotherapy approach. This review focuses on alternative approaches to active Abeta vaccination that are currently in various stages of development - from pre-clinical studies in animal models to current clinical trials. Specifically, the focus is on those strategies that target inflammatory and immune aspects of AD, and can therefore be classified as immunotherapeutic in a broad sense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.